The increasing use of in- and out-licensing agreements in the healthcare sector is influenced by various factors. These include the high development costs and risks of new drugs and technologies, the lack of internal expertise and the need to expand the product and patent portfolio.
For biotech and pharmaceutical companies, licensing agreements open up opportunities to gain access to innovative technologies and new markets while reducing financial and organizational risks. This is particularly important in order to remain competitive in a constantly changing industry.
In order to take full advantage of the benefits of in- and out-licensing, it is crucial to deal with the associated challenges.
